“Following the publication of Current Procedural Terminology (CPT) codes for treating non-melanoma skin cancer with SRT in November – with a per-fraction increase of more than 300% versus prior ...
CEO Joseph Sardano described Q1 2026 as “an important transition period” because “the dedicated CPT codes for Superficial Radiotherapy now in effect as of January 1” create “a fundamentally different ...
Sensus Healthcare outlines global expansion and regulatory milestones amid reimbursement uncertainty
Joseph C. Sardano, CEO, reported that domestic sales momentum was disrupted mid-quarter due to a proposed local coverage determination (LCD) that would limit reimbursement for ultrasound with the ...
BOCA RATON, Fla.--(BUSINESS WIRE)-- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments ...
The most recent trading session ended with Sensus Healthcare, Inc. (SRTS) standing at $6.42, reflecting a -0.47% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.16% ...
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced ...
Sensus Healthcare (NASDAQ:SRTS) is preparing to release its quarterly earnings on Thursday, 2026-02-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results